Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 2, 2013
Grant Date -
Aug 4, 2011
app pub date -
Apr 13, 2011
filing date -
May 17, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
First Claim
Other Claims data not available
